Announcement • Apr 28
HARBIN GLORIA PHARMACEUTICALS Co., LTD, Annual General Meeting, May 18, 2026 HARBIN GLORIA PHARMACEUTICALS Co., LTD, Annual General Meeting, May 18, 2026, at 15:00 China Standard Time. Location: 1F, Building 28, Ronghuiyuan, Yuhua Road, Area B, Airport Development Zone, Shunyi District, Beijing China Reported Earnings • Apr 15
Full year 2025 earnings released: EPS: CN¥0.17 (vs CN¥0.11 in FY 2024) Full year 2025 results: EPS: CN¥0.17 (up from CN¥0.11 in FY 2024). Revenue: CN¥2.14b (down 13% from FY 2024). Net income: CN¥376.9m (up 62% from FY 2024). Profit margin: 18% (up from 9.5% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Announcement • Mar 31
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report Q1, 2026 Results on Apr 28, 2026 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report Q1, 2026 results on Apr 28, 2026 Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥3.49, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 45% over the past three years. Announcement • Jan 16
Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 HARBIN GLORIA PHARMACEUTICALS Co., LTD at its Extraordinary General Meeting held on 14 January 2026, approved election of Xu Yuhong as an independent director. Announcement • Dec 31
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report Fiscal Year 2025 Results on Apr 28, 2026 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report fiscal year 2025 results on Apr 28, 2026 Board Change • Dec 13
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. Deputy GM & Non-Independent Director Kang Zhou is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: CN¥0.05 (vs CN¥0.028 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.05 (up from CN¥0.028 in 3Q 2024). Revenue: CN¥565.5m (down 11% from 3Q 2024). Net income: CN¥109.3m (up 87% from 3Q 2024). Profit margin: 19% (up from 9.2% in 3Q 2024). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report Q3, 2025 Results on Oct 29, 2025 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report Q3, 2025 results on Oct 29, 2025 Buy Or Sell Opportunity • Sep 19
Now 20% undervalued Over the last 90 days, the stock has risen 20% to CN¥3.36. The fair value is estimated to be CN¥4.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Aug 01
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥4.04, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 37x in the Pharmaceuticals industry in China. Total returns to shareholders of 66% over the past three years. New Risk • Jul 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Large one-off items impacting financial results. Announcement • Jul 02
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report First Half, 2025 Results on Aug 27, 2025 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report first half, 2025 results on Aug 27, 2025 Board Change • Jun 25
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. Deputy GM & Non-Independent Director Kang Zhou is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Buy Or Sell Opportunity • Jun 05
Now 21% undervalued Over the last 90 days, the stock has risen 15% to CN¥2.79. The fair value is estimated to be CN¥3.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Earnings per share has grown by 81%. Revenue is forecast to grow by 8.2% in a year. Earnings are forecast to decline by 0.02% in the next year. Valuation Update With 7 Day Price Move • May 29
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥3.07, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 26% over the past three years. New Risk • May 14
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 35% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 26
First quarter 2025 earnings released: EPS: CN¥0.027 (vs CN¥0.024 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.027 (up from CN¥0.024 in 1Q 2024). Revenue: CN¥551.3m (down 7.1% from 1Q 2024). Net income: CN¥60.3m (up 15% from 1Q 2024). Profit margin: 11% (up from 8.8% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Apr 26
HARBIN GLORIA PHARMACEUTICALS Co., LTD, Annual General Meeting, May 16, 2025 HARBIN GLORIA PHARMACEUTICALS Co., LTD, Annual General Meeting, May 16, 2025, at 15:00 China Standard Time. Location: 1F, Building 28, Ronghuiyuan, Yuhua Road, Area B, Airport Development Zone, Shunyi District, Beijing China Announcement • Mar 31
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report Q1, 2025 Results on Apr 26, 2025 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report Q1, 2025 results on Apr 26, 2025 Announcement • Mar 18
HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director HARBIN GLORIA PHARMACEUTICALS Co., LTD at its 2nd Extraordinary General Meeting of 2025 on 14 March 2025, approved Election of Liu Yueyin as a non-independent director. Announcement • Feb 08
HARBIN GLORIA PHARMACEUTICALS Co., LTD Announces Directorate Appointments HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that at the EGM held on 06 February 2025 approved the appointment of Shen Zhenyu as non-independent director and appointment of Chen Yi and Wang Lida as independent directors. Buy Or Sell Opportunity • Jan 06
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 3.0% to CN¥2.44. The fair value is estimated to be CN¥2.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 10% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 223% in the next 2 years. Announcement • Dec 31
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report Fiscal Year 2024 Results on Apr 26, 2025 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report fiscal year 2024 results on Apr 26, 2025 Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥2.76, the stock trades at a trailing P/E ratio of 78.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total returns to shareholders of 17% over the past three years. Buy Or Sell Opportunity • Nov 05
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 28% to CN¥2.44. The fair value is estimated to be CN¥2.01, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 10% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.028 (vs CN¥0.088 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.028 (down from CN¥0.088 in 3Q 2023). Revenue: CN¥636.2m (up 2.7% from 3Q 2023). Net income: CN¥58.5m (down 70% from 3Q 2023). Profit margin: 9.2% (down from 32% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Sep 30
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report Q3, 2024 Results on Oct 29, 2024 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥2.26, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 12% over the past three years. Reported Earnings • Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.032 (vs CN¥0.004 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.032 (up from CN¥0.004 in 2Q 2023). Revenue: CN¥628.2m (down 16% from 2Q 2023). Net income: CN¥72.7m (up CN¥64.5m from 2Q 2023). Profit margin: 12% (up from 1.1% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Jun 29
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report First Half, 2024 Results on Aug 24, 2024 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report first half, 2024 results on Aug 24, 2024 New Risk • May 10
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 65% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.024 (vs CN¥0.009 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.024 (up from CN¥0.009 in 1Q 2023). Revenue: CN¥593.1m (down 13% from 1Q 2023). Net income: CN¥52.3m (up 161% from 1Q 2023). Profit margin: 8.8% (up from 2.9% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Apr 21
HARBIN GLORIA PHARMACEUTICALS Co., LTD, Annual General Meeting, May 10, 2024 HARBIN GLORIA PHARMACEUTICALS Co., LTD, Annual General Meeting, May 10, 2024, at 15:00 China Standard Time. Announcement • Mar 30
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report Q1, 2024 Results on Apr 27, 2024 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report Q1, 2024 results on Apr 27, 2024 New Risk • Mar 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (3.3% increase in shares outstanding). New Risk • Feb 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Announcement • Dec 30
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report Fiscal Year 2023 Results on Apr 20, 2024 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report fiscal year 2023 results on Apr 20, 2024 New Risk • Oct 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.088 (vs CN¥0.001 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.088 (up from CN¥0.001 in 3Q 2022). Revenue: CN¥619.3m (down 24% from 3Q 2022). Net income: CN¥195.4m (up CN¥192.1m from 3Q 2022). Profit margin: 32% (up from 0.4% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Jul 29
Second quarter 2023 earnings released: EPS: CN¥0.004 (vs CN¥0.011 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.004 (down from CN¥0.011 in 2Q 2022). Revenue: CN¥751.5m (down 8.9% from 2Q 2022). Net income: CN¥8.19m (down 68% from 2Q 2022). Profit margin: 1.1% (down from 3.1% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Buying Opportunity • Jul 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 10%. The fair value is estimated to be CN¥2.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.3% over the last 3 years. Meanwhile, the company became loss making. Announcement • Jul 01
HARBIN GLORIA PHARMACEUTICALS Co., LTD to Report First Half, 2023 Results on Jul 29, 2023 HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that they will report first half, 2023 results on Jul 29, 2023 Buying Opportunity • Jun 08
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be CN¥2.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.3% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Apr 24
First quarter 2023 earnings released: EPS: CN¥0.009 (vs CN¥0.001 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.009 (up from CN¥0.001 in 1Q 2022). Revenue: CN¥681.2m (down 12% from 1Q 2022). Net income: CN¥20.1m (up CN¥19.1m from 1Q 2022). Profit margin: 2.9% (up from 0.1% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Dec 22
Harbin Gloria Pharmaceuticals Co., Ltd Announces Executive Appointments Harbin Gloria Pharmaceuticals Co. Ltd. at its EGM held on 20 December appointed Pan Min, Jiang Minghui and Zhang Xiaodan as independent directors. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Jin Hu was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Nov 15
Harbin Gloria Pharmaceuticals Co., Ltd Approves Executive Appointments Harbin Gloria Pharmaceuticals Co. Ltd. at its 1st Extraordinary General Meeting of 2022 on 11 November 2022 approved Election of Guo Leifeng as non-independent directors andCheng Yuehong as shareholder supervisors. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.001 (vs CN¥0.002 loss in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.001 (up from CN¥0.002 loss in 3Q 2021). Revenue: CN¥815.5m (up 4.4% from 3Q 2021). Net income: CN¥3.23m (up CN¥7.31m from 3Q 2021). Profit margin: 0.4% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 29
Second quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.042 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.011 (down from CN¥0.042 in 2Q 2021). Revenue: CN¥825.4m (flat on 2Q 2021). Net income: CN¥25.9m (down 72% from 2Q 2021). Profit margin: 3.1% (down from 11% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: CN¥0.001 (vs CN¥0.01 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.001 (down from CN¥0.01 in 1Q 2021). Revenue: CN¥774.2m (up 9.8% from 1Q 2021). Net income: CN¥998.3k (down 95% from 1Q 2021). Profit margin: 0.1% (down from 3.1% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Non-Independent Director Jin Hu was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Jan 30
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Non-Independent Director Jin Hu was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 31
Third quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.005 loss in 3Q 2020) The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: CN¥780.8m (down 3.6% from 3Q 2020). Net loss: CN¥4.07m (loss narrowed 64% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 29
Second quarter 2021 earnings released: EPS CN¥0.042 (vs CN¥0.005 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥832.2m (up 1.0% from 2Q 2020). Net income: CN¥92.7m (up CN¥82.3m from 2Q 2020). Profit margin: 11% (up from 1.3% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 18
Full year 2020 earnings released: EPS CN¥0.18 (vs CN¥1.21 loss in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥3.05b (down 40% from FY 2019). Net income: CN¥400.0m (up CN¥3.06b from FY 2019). Profit margin: 13% (up from net loss in FY 2019). The move to profitability was driven by lower expenses. Is New 90 Day High Low • Jan 25
New 90-day low: CN¥2.82 The company is down 10.0% from its price of CN¥3.12 on 27 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day low: CN¥2.91 The company is down 13% from its price of CN¥3.34 on 17 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Is New 90 Day High Low • Oct 30
New 90-day low: CN¥2.99 The company is down 28% from its price of CN¥4.15 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥2.31b, with earnings decreasing by CN¥2.41b from the prior year. Total revenue was CN¥3.29b over the last 12 months, down 40% from the prior year. Announcement • Oct 20
Harbin Gloria Pharmaceuticals Co., Ltd to Report Q3, 2020 Results on Oct 28, 2020 Harbin Gloria Pharmaceuticals Co., Ltd announced that they will report Q3, 2020 results on Oct 28, 2020 Is New 90 Day High Low • Sep 28
New 90-day low: CN¥3.09 The company is down 4.0% from its price of CN¥3.23 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Announcement • Aug 12
Harbin Gloria Pharmaceuticals Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020 Harbin Gloria Pharmaceuticals Co., Ltd announced that they will report first half, 2020 results on Aug 28, 2020